Psora-4

Psora-4
Identifiers
	IUPAC name 4-(4-phenylbutoxy)furo[3,2-g]chromen-7-one;
CAS Number	724709-68-6;
PubChem CID	6603977;
IUPHAR/BPS	9583;
ChemSpider	5036283;
UNII	QDY3FLF2DY;
ChEBI	CHEBI:183514;
ChEMBL	ChEMBL1256851;
CompTox Dashboard (EPA)	DTXSID10424970 ;
Chemical and physical data
Formula	C21H18O4
Molar mass	334.371 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC=C(C=C1)CCCCOC2=C3C=CC(=O)OC3=CC4=C2C=CO4;
	InChI InChI=1S/C21H18O4/c22-20-10-9-16-19(25-20)14-18-17(11-13-23-18)21(16)24-12-5-4-8-15-6-2-1-3-7-15/h1-3,6-7,9-11,13-14H,4-5,8,12H2; Key:JJAWGNIQEOFURP-UHFFFAOYSA-N;

Psora-4 is an experimental drug that acts as a selective inhibitor of the K_v1.3 potassium channel. It has immunomodulatory effects, suppressing the proliferation of memory T cells, but increases neural progenitor cell proliferation and has lifespan-extending effects in animal studies.^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]

References

^ Vennekamp J, Wulff H, Beeton C, Calabresi PA, Grissmer S, Hänsel W, et al. (June 2004). "Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators". Molecular Pharmacology. 65 (6): 1364–1374. doi:10.1124/mol.65.6.1364. PMID 15155830.
^ Liebau S, Pröpper C, Böckers T, Lehmann-Horn F, Storch A, Grissmer S, et al. (October 2006). "Selective blockage of Kv1.3 and Kv3.1 channels increases neural progenitor cell proliferation". Journal of Neurochemistry. 99 (2): 426–437. doi:10.1111/j.1471-4159.2006.03967.x. PMID 17029597.
^ Hyodo T, Oda T, Kikuchi Y, Higashi K, Kushiyama T, Yamamoto K, et al. (December 2010). "Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis". American Journal of Physiology. Renal Physiology. 299 (6): F1258 – F1269. doi:10.1152/ajprenal.00374.2010. PMC 3006300. PMID 20810612.
^ Ueyama A, Imura K, Kasai-Yamamoto E, Tai N, Nagira M, Shichijo M, et al. (December 2013). "Kv1.3 blockers ameliorate allergic contact dermatitis by preferentially suppressing effector memory T cells in a rat model". Clinical and Experimental Dermatology. 38 (8): 897–903. doi:10.1111/ced.12097. PMID 24252082.
^ Zhou YY, Hou GQ, He SW, Xiao Z, Xu HJ, Qiu YT, et al. (July 2015). "Psora-4, a Kv1.3 Blocker, Enhances Differentiation and Maturation in Neural Progenitor Cells". CNS Neuroscience & Therapeutics. 21 (7): 558–567. doi:10.1111/cns.12402. PMC 6495590. PMID 25976092.
^ Admasu TD, Chaithanya Batchu K, Barardo D, Ng LF, Lam VY, Xiao L, et al. (October 2018). "Drug Synergy Slows Aging and Improves Healthspan through IGF and SREBP Lipid Signaling". Developmental Cell. 47 (1): 67–79.e5. doi:10.1016/j.devcel.2018.09.001. PMID 30269951.
^ Admasu TD, Barardo D, Ng LF, Batchu KC, Cazenave-Gassiot A, Wenk MR, et al. (April 2022). "A small-molecule Psora-4 acts as a caloric restriction mimetic to promote longevity in C. elegans". GeroScience. 44 (2): 1029–1046. doi:10.1007/s11357-021-00374-6. PMC 9135947. PMID 33988831.
^ Sastre D, Colomer-Molera M, de Benito-Bueno A, Valenzuela C, Fernández-Ballester G, Felipe A (August 2024). "KCNE4-dependent modulation of Kv1.3 pharmacology". Biochemical Pharmacology. 226: 116368. doi:10.1016/j.bcp.2024.116368. hdl:10261/363770. PMID 38880360.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[1] Vennekamp J, Wulff H, Beeton C, Calabresi PA, Grissmer S, Hänsel W, et al. (June 2004). "Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators". Molecular Pharmacology. 65 (6): 1364–1374. doi:10.1124/mol.65.6.1364. PMID 15155830.

[2] Liebau S, Pröpper C, Böckers T, Lehmann-Horn F, Storch A, Grissmer S, et al. (October 2006). "Selective blockage of Kv1.3 and Kv3.1 channels increases neural progenitor cell proliferation". Journal of Neurochemistry. 99 (2): 426–437. doi:10.1111/j.1471-4159.2006.03967.x. PMID 17029597.

[3] Hyodo T, Oda T, Kikuchi Y, Higashi K, Kushiyama T, Yamamoto K, et al. (December 2010). "Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis". American Journal of Physiology. Renal Physiology. 299 (6): F1258 – F1269. doi:10.1152/ajprenal.00374.2010. PMC 3006300. PMID 20810612.

[4] Ueyama A, Imura K, Kasai-Yamamoto E, Tai N, Nagira M, Shichijo M, et al. (December 2013). "Kv1.3 blockers ameliorate allergic contact dermatitis by preferentially suppressing effector memory T cells in a rat model". Clinical and Experimental Dermatology. 38 (8): 897–903. doi:10.1111/ced.12097. PMID 24252082.

[5] Zhou YY, Hou GQ, He SW, Xiao Z, Xu HJ, Qiu YT, et al. (July 2015). "Psora-4, a Kv1.3 Blocker, Enhances Differentiation and Maturation in Neural Progenitor Cells". CNS Neuroscience & Therapeutics. 21 (7): 558–567. doi:10.1111/cns.12402. PMC 6495590. PMID 25976092.

[6] Admasu TD, Chaithanya Batchu K, Barardo D, Ng LF, Lam VY, Xiao L, et al. (October 2018). "Drug Synergy Slows Aging and Improves Healthspan through IGF and SREBP Lipid Signaling". Developmental Cell. 47 (1): 67–79.e5. doi:10.1016/j.devcel.2018.09.001. PMID 30269951.

[7] Admasu TD, Barardo D, Ng LF, Batchu KC, Cazenave-Gassiot A, Wenk MR, et al. (April 2022). "A small-molecule Psora-4 acts as a caloric restriction mimetic to promote longevity in C. elegans". GeroScience. 44 (2): 1029–1046. doi:10.1007/s11357-021-00374-6. PMC 9135947. PMID 33988831.

[8] Sastre D, Colomer-Molera M, de Benito-Bueno A, Valenzuela C, Fernández-Ballester G, Felipe A (August 2024). "KCNE4-dependent modulation of Kv1.3 pharmacology". Biochemical Pharmacology. 226: 116368. doi:10.1016/j.bcp.2024.116368. hdl:10261/363770. PMID 38880360.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]